KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
Medves
S
S
Duhoux
F P
FP
Ferrant
A
A
Toffalini
F
F
Ameye
G
G
Libouton
J-M
JM
Poirel
H A
HA
Demoulin
J-B
JB
D048868:Adaptor Proteins, Signal Transducing; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D003598:Cytoskeletal Proteins; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics*; D013922:Thrombocytosis / Q000188:drug therapy / Q000209:etiology*; D014178:Translocation, Genetic; D025521:Tumor Suppressor Proteins / Q000235:genetics*
D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; D001549:Benzamides; D003598:Cytoskeletal Proteins; C467739:KANK1 protein, human; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D025521:Tumor Suppressor Proteins; D000068877:Imatinib Mesylate; D020797:Receptor, Platelet-Derived Growth Factor beta